Conduit Pharmaceuticals Inc.
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, whic… Read more
Conduit Pharmaceuticals Inc. (CDT) - Total Liabilities
Latest total liabilities as of December 2025: $2.22 Billion USD
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has total liabilities worth $2.22 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Conduit Pharmaceuticals Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Conduit Pharmaceuticals Inc. Competitors by Total Liabilities
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infinitum Copper Corp
OTCQB:INUMF
|
USA | $891.31K |
|
Aspira Womens Health Inc
NASDAQ:AWH
|
USA | $8.05 Million |
|
Tali Digital Ltd
AU:TD1
|
Australia | AU$487.56K |
|
Loyal Solutions AS
ST:LOYAL
|
Sweden | Skr53.19 Million |
|
LafargeHolcim Ltd
MU:HLBN
|
Germany | €25.90 Billion |
|
MX Gold Corp
PINK:MXLGF
|
USA | $1.37 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Conduit Pharmaceuticals Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Conduit Pharmaceuticals Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual total liabilities of Conduit Pharmaceuticals Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.22 Billion | +20063.31% |
| 2024-12-31 | $10.99 Million | +43.03% |
| 2023-12-31 | $7.68 Million | -23.91% |
| 2022-12-31 | $10.09 Million | +5143.47% |
| 2021-12-31 | $192.51K | -- |